Portal venous thrombosis in a young patient with idiopathic myelofibrosis and intrahepatic extramedullary hematopoiesis: a difficult diagnosis, prognosis and management Chronic myeloproliferative syndromes (MPSs) occur much less commonly in children than in adults. Idiopathic myelofibrosis (IMF) is characterized by stem cell-derived clonal myeloproliferation and shows constitutional symptoms, increasing splenomegaly, bone marrow fibrosis, extramedullary hematopoiesis, progressive anemia and cytopenias; hemorrhages and above all thrombosis are frequent complications. 1 Portal vein thrombosis (PVT) is associated with liver cirrhosis, hepatocellular carcinoma, intra-abdominal infections, hemodynamic factors, hypercoagulability states and thrombophilic disorders, including MPS. 2 Chronic PVT can be often recognized casually, after a fortuitous diagnosis of hypersplenism or portal hypertension or while having biliary symptoms related to cholangiopathy or only initial ascites; moreover, acute PVT can present with life-threatening events such as gastrointestinal hemorrhage and intestinal infarction. The PVT can result from the concurrence of several acquired factors, with or without the presence of genetic ones. Cirrhotic PVT patients usually have an advanced liver disease; in these patients, the concomitant mutation G20210A of the prothrombin gene increases more than fivefold the risk. 3 About 70% of patients with PVT have a general risk factor, most commonly MPS, while local precipitating risk factors, such as an abdominal inflammatory focus, can be identified in about 30%. A moderate hyperhomocysteinemia is associated with heightened risk, 4 and PVT has been reported in patients with antiphospholipid syndrome. 5 PVT in children or young adults is reported anecdotically. 4 A girl was referred for isolated thrombocytosis (median 700 Â 10 3 ml À1 ) since she was 2 years old. The bone marrow was hypercellular, with numerous clusters of megakaryocytes; EPO-independent BFU-E colonies were demonstrated; the karyotype was normal and bcr-abl rearrangements were absent. A childhood essential thrombocythemia (ET) was initially diagnosed, while excluding a familial disease. At the age of 9, the spleen was at the upper normal limit, while showing an increase afterwards: at 16 and 20 years, there was a slight splenomegaly (surface 75 and 80 cm 2 , respectively), while showing only a moderate and steady thrombocytosis. The thrombophilic study (lupus anticoagulant, anticardiolipin, antiphospholipid, anti-b 2 glycoprotein I antibodies, lipoprotein a, ATIII, protein S and C, activated protein C resistance, factor V Leiden G1691A and prothrombin gene G20210A mutations) resulted negative; she was only heterozygous for MTHFR C677T mutation without hyperhomocysteinemia. A watch-and-wait strategy seemed appropriate in this asymptomatic case, platelet count remaining only moderately elevated, and lowdose aspirin was started. In January 2006, when she was 23 years old, the girl showed increasing thrombocytosis (1500 Â 10 3 ml À1 ), slight leukocytosis (18 Â 10 3 ml À1 ) with neutrophilia (13.1 Â 10 3 ml À1 ) and without basophilia and eosino-philia, increased splenomegaly (90 cm 2 ) and no anemia (Hb 12.9 g/dl). She complained of an abdominal pain and mild oral bleeding: a gastroscopy revealed an initial erosive duodenitis without helicobacter pylori infection. At this time, the trephine biopsy showed increased clusters of hyperlobulated megakaryocytes and fibrosis: the histopathologist leaned more towards an IMF than for an ET. EPO-independent BFU-E colonies were present, there were neither cytogenetic abnormalities nor bcr-abl rearrangements, but the JAK2 V617F mutation in heterozygous state was demonstrated. Leukocytic alkaline phospha- tase was high, while we did not find leukoerythroblastic blood reaction and teardrop erythrocytes on blood count, typical of IMF, and the absolute content of CD34 þ cells in the peripheral blood was not high (7.0 Â 10 6 l À1 ). After a cardiologic study, she started therapy with anagrelide. Some weeks before the therapy, she had developed an increase in liver tests and above all cholestatic indices, with a slight homogeneous hepatomegaly, even if she remained asymptomatic; all herpesviridae were negative. A magnetic resonance imaging (MRI) demonstrated splenomegaly without nodular lesions but with multiple infarcts and various hepatic pathologic areas (Figure 1a) . The ultrasound-guided fine needle hepatic biopsy showed focal intrahepatic extramedullary hematopoiesis (IEH) (Figures 2a and b) . The vascular MRI study completed with Doppler color flow imaging demonstrated in the pancreatic area numerous convoluted blood vessels going towards spleno-mesenteric-portal convergence to constitute a big portal cavernoma associated to multiple collateral venous circles and with the fibrotic transformation of portal vein (common portal vein and right and left branches), and filiform splenic vein with reduced blood flow (Figures 1a-c) . Gastroscopy did not reveal ulcerative lesions or varices. A repeated bone marrow trephine biopsy showed a diffuse pattern of fibrosis, IMF grade II (Figures 2c and  d) . Hydroxyurea was started, together with oral anticoagulation; however, we have initiated a research for allogeneic hematopoietic stem cell transplantation (HSCT).
IMF can be associated with myeloid metaplasia in the spleen, liver (IEH) and even unusual sites, like lymph nodes, gall bladder, kidneys, ureters, bladder, thorax, esophagus, lacrimal fossae and nasolacrimal ducts. Some histological studies of the liver involvement in IMF have demonstrated that IEH primarily consists of the presence of morphologically abnormal megakaryocytes, an increased reticulin network, sinusoidal widening and iron overload. High serum alkaline phosphatase is the most frequent biochemical abnormality in IEH, as observed in our patient.
IMF is an uncommon disorder in young individuals and its clinical course is variable, with some patients surviving some months and others showing a prolonged indolent course. Cervantes 6 has described three prognostic clinical and laboratory parameters in patients aged p55 years: anemia, general symptoms and circulating blasts. Regarding this scoring system, our young patient belongs to a low-risk group, even if she has a clinical progressive IMF, as suggested by the hepatic myeloid metaplasia, multiple splenic infarcts and PVT; so we have initiated the research for allogeneic HSCT.
This is an unusual case of a juvenile IMF, with a clinical history beginning at the age of 2 years and lasting more than 20 years; above all it is one of the first complicated by PVT.
The thrombophilic study result was negative; it is supposable that the reduced hepatopetal flow, secondary to the sinusoidal obstruction given by the focal IEH, constituted a predisposing factor for PVT together with the thrombophilic condition of the IMF itself; it is noteworthy that the JAK2 mutation is frequently found in PVT patients. We suggest that even young patients showing increased cholestatic indices must be monitored for IEH; in these patients, PVT must be prevented and finally diagnosed at the right time and eventually treated.
As the choice of therapy (cytoreductive and anticoagulant therapy) is problematic even because of young age; 7 anagrelide seems to be a promising approach for young adults with thrombocytosis in MPSs, in particular ET, because of the selective activity against platelet production and the mild toxicity, absent leukemogenic effect and the good compliance by patients. Nevertheless, despite the complete hematologic response and good tolerance, it has been changed to hydroxyurea, because the latter has a major efficacy in preventing venous thrombosis and reducing bone marrow fibrosis and splenomegaly; its possible long term leukemogenic effect has not been demonstrated. 1, 7 Furthermore warfarin has been started, mainly as a secondary prophylaxis to reduce the risk of recurrence of PVT. It is not yet clear which is the best duration of oral anticoagulation (3 or 6 months or long life); 8 perhaps it appears appropriate to continue with long-term prophylaxis since MPS, in particular IMF, is an important and above all persistent risk factor. Regarding allogeneic HSCT, it is the only real curative option for IMF but is associated with significant morbidity and mortality, in particular with standard-dose conditioning regimens, so that this therapeutic option often remains controversial.
